Skip Nav Destination
Advances in Brief
In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
J P Perentesis; R Gunther; B Waurzyniak; Y Yanishevski; D E Myers; O Ek; Y Messinger; Y Shao; L M Chelstrom; E Schneider; W E Evans; F M Uckun
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
R J Morgan, Jr; J H Doroshow; K Venkataraman; K Chang; J Raschko; G Somlo; L Leong; M Tetef; S Shibata; V Hamasaki; K Margolin; S Forman; S Akman; P Coluzzi; C Ahn; L Weiss; U Gadgil; J Harrison
Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
S Chevillard; J Lebeau; P Pouillart; C de Toma; C Beldjord; B Asselain; J Klijanienko; A Fourquet; H Magdelénat; P Vielh
Foundations of Clinical Cancer Research: Perspective for the 21st Century
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
A R Zander; C Berger; N Kröger; M Stockshläder; W Krüger; M Horstmann; J Grimm; W Zeller; H Kabisch; R Erttmann; P Schönrock; R Kuse; D Braumann; H J Illiger; W Fiedler; M de Witt; K D Hossfeld; H J Weh